(R)-5-(1-amino-1-oxobutan-2-ylamino)-3-(5-methylpyridin-3-ylamino)pyrazine-2-carboxamide | 1438420-86-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (R)-5-(1-amino-1-oxobutan-2-ylamino)-3-(5-methylpyridin-3-ylamino)pyrazine-2-carboxamide
• 英文别名: 5-[[(2R)-1-amino-1-oxobutan-2-yl]amino]-3-[(5-methylpyridin-3-yl)amino]pyrazine-2-carboxamide
• CAS: 1438420-86-0
• 化学式: C₁₅H₁₉N₇O₂
• 分子量: 329.362
• InChiKey: NGHXLNSQNKEBTC-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  149
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• PYRAZINE KINASE INHIBITORS
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20130131040A1

  公开（公告）日：2013-05-23

  Provided are pyrazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

  提供了用于抑制Syk激酶的吡嗪化合物，用于制备这些化合物的中间体，它们的制备方法，药物组合物，抑制Syk激酶活性的方法，以及治疗至少在一定程度上由Syk激酶活性介导的疾病的方法。
• Pyrazine Kinase Inhibitors
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20140309209A1

  公开（公告）日：2014-10-16

  Provided are pyrazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

  提供了吡嗪化合物，用于抑制Syk激酶，用于制备这些化合物的中间体，其制备方法，药物组合物，用于抑制Syk激酶活性的方法，以及用于治疗至少部分由Syk激酶活性介导的疾病的方法。
• US8877760B2
  申请人：——

  公开号：US8877760B2

  公开（公告）日：2014-11-04
• US9359308B2
  申请人：——

  公开号：US9359308B2

  公开（公告）日：2016-06-07
• [EN] PYRAZINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE DE LA PYRAZINE KINASE
  申请人：PORTOLA PHARM INC

  公开号：WO2013078466A1

  公开（公告）日：2013-05-30

  Provided are pyrazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.